Abstract 181P
Background
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in a variety of cancer patient cohorts, reflecting the key role of TLSs in the initiation of tumor-targeting immunity. Although, the clinical and biological relevance of TLSs, B cells, plasma cells and humoral adaptive immunity for patients with EOC have been previously reported, the precise immune contexture of developing TLSs, their impact the phenotypic profile of intratumoral T cells, and their influence on sensitivity to immunotherapy remain to be investigated in detail.
Methods
We harnessed spatial transcriptomics, multiplex immunofluorescence microscopy, and flow cytometry to characterize TLSs in patients with high-grade serous ovarian carcinoma (HGSOC), non-small cell lung carcinoma (NSCLC) and experimental mouse models.
Results
Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) were associated with an increased intratumoral density of CD8+ effector T (TEFF) cells and TIM3+PD1+, hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8+ T cells. Converesely, CD8+ T cells from immunologically hot tumors like non-small cell lung carcinoma (NSCLC) were enriched in ICI-responsive TCF1+ PD1+ T cells. Spatial B-cell profiling identified patterns of in situ maturation and differentiation that were associated with mTLSs. Moreover, B-cell depletion promoted signs of a dysfunctional CD8+ T cell compartment among tumor-infiltrating lymphocytes from freshly isolated HGSOC and NSCLC biopsies.
Conclusions
Taken together, our data demonstrate that – at odds with NSCLC – HGSOC is associated with a low density of follicular helper T cells and thus develops a limited number of mTLS that are insufficient to preserve a ICI-sensitive TCF1+PD1+ CD8+ T cell phenotype. These findings point to key quantitative and qualitative differences between mTLSs in ICI-responsive vs ICI-irresponsive neoplasms that may guide the development of alternative immunotherapies for patients with HGSOC.
Legal entity responsible for the study
The authors.
Funding
Sotio Biotech.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1P - Integrated Data Analysis within IMMUcan Identifies Prognostic Features of Early NSCLC
Presenter: Daniel Schulz
Session: Poster Display
3P - Exploratory efficacy analysis by smoking status in PD-L1 high patients in the phase III, non-small cell lung cancer (NSCLC) IMpower110 study
Presenter: Luis Paz-Ares
Session: Poster Display
4P - Immune exoproteome, soluble proteome and immune-related gene expression profiles of anti-PD-1 therapy in stage IIIB/IV Non-Small Cell Lung Cancer: relevance of immunosuppressive factors
Presenter: Paulo Santos
Session: Poster Display
5P - Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC
Presenter: Giulia Mazzaschi
Session: Poster Display
6P - CD161+CD127+CD8+ T cells as a critical predictor of the efficacy of anti-PD-1 immunotherapy in diabetic patients with non-small cell lung cancer
Presenter: Jingjing Qu
Session: Poster Display
7P - A T-cell-derived circulating DNA as a biomarker for response to anti-PD(L)1 immunotherapy in advanced stage non-small cell lung cancer
Presenter: Nuthchaya Mejun
Session: Poster Display
9P - Primary NSCLC patient-derived microtumors (PMTs) for clinical-relvant prediction of immunotherapy efficacy
Presenter: Fabienne Nocera
Session: Poster Display
11P - Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
Presenter: Liang Zheng
Session: Poster Display
12P - Spatially preserved multi-region transcriptomic subtyping and biomarkers associated with long-term benefit with chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC)
Presenter: Melina Peressini Álvarez
Session: Poster Display